Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2833-2839

  Pratesi, Graziella ^a   De Cesare, Michelandrea ^a   Caserini, Claudia ^a   Perego, Paola ^a   Dal Bo, Laura ^a   Polizzi, Donatella ^a   Supino, Rosanna ^a   Bigioni, Mario ^b   Manzini, Stefano ^b   Iafrate, Elisabetta ^b   Salvatore, Carmela ^b   Casazza, Annamaria ^c   Arcamone, Federico ^b   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Menarini Ricerche SpA   (Italy)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DISACCHARIDE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; PROTEIN BCL 2; SABARUBICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA; DISACCHARIDES; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031754801     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Arcamone, F. Doxorubicin, Anticancer Antibiotics. New York: Academic Press, 1981.
2. Weiss, R. B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol., 19: 670-686, 1992.
3. Di Marco, A., Casazza, A. M., Gambetta, R., Supino, R., and Zunino, F. Relationship between activity and amino sugar stereochemistry of daunorubicin and adriamycin derivatives. Cancer Res., 36: 1962-1966, 1976.
4. Zunino, F., and Capranico, G. DNA topoisomerase II as the primary target of antitumor anthracyclines. Anticancer Drug Design, 5: 307-317, 1992.
5. Gresh, N., Pullman, B., Arcamone, F., Menozzi, M., and Tonani, R. Joint experimental and theoretical investigations of the comparative DNA binding affinities of intercalating anthracycline derivatives. Mol. Pharmacol., 35: 251-256, 1988.
6. Priebe, W., Van, N. T., Burke, T. G., and Perez-Soler, R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs, 4: 37-48, 1993.
7. Capranico, G., Supino, R., Binaschi, M., Capolongo, L., Grandi, M., Suarato, A., and Zunino, F. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol., 45: 908-915, 1994.
8. Animati, F., Berettoni, M., Cipollone, A., Franciotti, M., Lombardi, P., Monteagudo, E., and Arcamone, F. New anthracycline disaccharides synthesis of L-daunosaminyl-α(1→4)-2-deoxy-L-rhamnosyl and of L-daunosaminyl-α(1→4)-2-deoxy-L-fucosyl daunorubicin analogues. J. Chem. Soc. Perkin Trans. 1: 1327-1329, 1996.
9. Smid, P., de Ruiter, G. A., van der Marel, G. A., Rombouts, F. M., and van Boom, J. H. Iodorium-ion assisted stereospecific glycosylation synthesis of oligosaccharides containing α(1-4)-linked L-glycopyranosyl units. J. Carbohydr. Chem., 10: 833-849, 1991.
10. Arcamone, F., Animati, F., Berettoni, M., Bigioni, M., Capranico, G., Casazza, A. M., Caserini, C., Cipollone, A., De Cesare, M., Franciotti, M., Lombardi, P., Madami, A., Manzini, S., Monteagudo, E., Polizzi, D., Pratesi, G., Righetti, S. C., Salvatore, C., Supino, R., and Zunino, F. Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J. Natl. Cancer Inst., 89: 1217-1223, 1997.
11. Houghton, J. A., and Houghton, P. J. The suitability and use of human tumor xenografts., In: R. F. Kallman (ed.), Rodent Tumor Models in Experimental Cancer Therapy, pp. 199-204, New York: Pergamon Press, 1987.
12. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
13. Supino, R. MTT assays. In: S. O'Hare and C. K. Atterwill (eds.), Methods in Molecular Biology: in Vitro Toxicity Testing Protocols, Vol. 43, pp. 137-149. Totowa, NJ: Humana Press Inc., 1995.
14. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br. J. Cancer, 58: 109-113, 1988.
15. Pratesi, G., Manzotti, C., Tortoreto, M., Prosperi, E., and Zunino, F. Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts. Tumori, 75: 60-65, 1989.
16. Mazue', G., Iatropoulos, M., Imondi, A., Castellino, S., Brughera, M., Podesta', A., Della Torre, P., and Moneta, D. Anthracyclines: a review of general and special toxicity studies. Int. J. Oncol., 7: 713-726, 1995.
17. De Cesare, M., Pratesi, G., Giusti, A., Polizzi, D., and Zunino, F. Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts. Br. J. Cancer, 77: 434-439, 1998.
18. Haldar, S., Jena, N., and Croce, C. M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4507-4511, 1995.
19. Kubota, T., Matsuzaki, S. W., Hoshiya, Y., Watanabe, M., Kitajima, M., Asanuma, F., Yamada, Y., and Koh, J. I. Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J. Surg. Oncol., 64: 115-121, 1997.
20. McVie, J. G. Non-small cell lung cancer: meta-analysis of efficacy of chemotherapy. Semin. Oncol., 23: 12-14, 1996.
21. McVie, G., and Thatcher, N. Commitment demanded for lung cancer research. Ann. Oncol., 6: 979, 1995.
22. Lai, S-L., Goldstein, L. J., Gottesman, M. M., Pastan, I., Tsai, C-M., Johnson, B. E., Mulshine, J. L., Ihde, D. C., Kayser, K., and Gazdar, A. F. MDR1 gene expression in lung cancer. J. Natl. Cancer Inst., 81: 1144-1150, 1989.
23. Kreis, W. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest., 13: 296-312, 1995.
24. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman D. E., and Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
25. Zunino, F., Perego, P., Pilotti, S., Pratesi, G., Supino, R., and Arcamone, F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol. Ther., 76: 177-185, 1997.
26. Haldar, S., Chintapalli, J., and Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.
27. Apakama, I., Robinson, M. C., Walter, N. M., Charlton, R. G., Royds, J. A., Fuller, C. E., Neal, D. E., and Hamdy, F. C. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br. J. Cancer, 74: 1258-1262, 1996.